These novel therapies , Retatrutide, represent a remarkable advancement in addressing type 2 diabetes and conceivably other conditions . They are grouped as GLP-1 receptor agonists , meaning they to mimic the natural GLP-1 peptide, enhancing metabolic production and lowering hunger . Despite Semaglutide each operates relatively similarly, they vary